Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626 is registered in ClinicalTrials.gov with Aulos Bioscience, Inc. as lead sponsor.

NCT NCT05267626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05267626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Lead sponsor
Aulos Bioscience, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 4, 2022
Completion date
February 28, 2027
Enrollment
159 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cutaneous melanoma, metastatic cancer, non-small cell lung cancer